STEX / Streamex Corp. - Zgłoszenia SEC, Raport roczny, o pełnomocnictwie

Streamex Corp. and Orca Announce Launch of 24/7 Decentralized Secondary Liquidity Infrastructure for Tokenized Securities; GLDY the Inaugural Asset

Exhibit 99.1 Streamex Corp. and Orca Announce Launch of 24/7 Decentralized Secondary Liquidity Infrastructure for Tokenized Securities; GLDY the Inaugural Asset WINTER PARK, Fla., May 27, 2026 — Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a technology company building the tokenization ecosystem for all real-world assets beginning with commodities, today announced the launch of 24/

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 27, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 27, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State (Commission (I.R.S. Employer of incorporation) File Number) Iden

Streamex Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and Design

Exhibit 99.1 Streamex Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and Design WINTER PARK, Fla., May 26, 2026 — Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a technology company building the tokenization ecosystem for all real-world assets beginning with commodities, today announced the appointment of Kori Handy as Vice Pr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 26, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 26, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State (Commission (I.R.S. Employer of incorporation) File Number) Iden

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 STREAMEX COR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2026 STREAMEX CORP. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2026 STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of incorporat

AMENDED EMPLOYMENT AGREEMENT

Exhibit 10.2 AMENDED EMPLOYMENT AGREEMENT THIS AMENDED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into, BETWEEN: STREAMEX CORP., a company incorporated under the laws of the State of Delaware and having an office at 2431 Aloma Ave., Suite 243, Winter Park, Florida 32792. (the “Company”) OF THE FIRST PART AND: HENRY McPHIE, a person with a residence at 240 Sandringham Crescent North Vancouve

AMENDED EMPLOYMENT AGREEMENT

Exhibit 10.1 AMENDED EMPLOYMENT AGREEMENT THIS AMENDED EMPLOYMENT AGREEMENT (the “Agreement”) is effective as of the date of the last signature, BETWEEN: STREAMEX CORP., a company incorporated under the laws of the State of Delaware and having an office at 2431 Aloma Ave., Suite 243, Winter Park, Florida 32792. (the “Company”) OF THE FIRST PART AND: MITCHELL YOUNG WILLIAMS, a person with a residen

AMENDED EMPLOYMENT AGREEMENT

Exhibit 10.3 AMENDED EMPLOYMENT AGREEMENT THIS AMENDED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into, BETWEEN: STREAMEX CORP., a company incorporated under the laws of the State of Delaware and having an office at 2431 Aloma Ave., Suite 243, Winter Park, Florida 32792. (the “Company”) OF THE FIRST PART AND: MORGAN LEKSTROM, a person with a residence at 757 Orwell Street Unit 1North Vancou

EX-99.1

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 8, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 8, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State (Commission (I.R.S. Employer of incorporation) File Number) Ide

COMMON STOCK PURCHASE WARRANT BIOSIG TECHNOLOGIES, INC.

EXHIBIT 4.35 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

EXHIBIT 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 27, 2026, Streamex Corp. (formerly BioSig Technologies, Inc.), a Delaware corporation (the “Company”), has one class of securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended: shares of the Company’s common stock, par value $0.001 pe

COMMON STOCK PURCHASE WARRANT BIOSIG TECHNOLOGIES, INC.

EXHIBIT 4.34 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 Or ☐ TRANSITION REPORT UNDER SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38659 STREAMEX CORP. (Exact name of re

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a) AND RULE 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO

EXHIBIT 31.02 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a) AND RULE 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Christine Plummer, certify that: 1. I have reviewed this annual report on Form 10-K of Streamex Corp; 2. Based on my knowledge, this report does not contain any untrue statemen

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

EXHIBIT 32.01 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Henry McPhie, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Streamex Corp. on Form 10-K for the fiscal year ended December 31, 2025 fully

COMMON STOCK PURCHASE WARRANT VIRALCLEAR PHARMACEUTICALS, INC. F/K/A NEUROCLEAR TECHNOLOGIES, INC.

Exhibit 4.36 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Subsidiaries of the Registrant1

EXHIBIT 21.1 Subsidiaries of the Registrant1 Name of Company Jurisdiction of Organization 1540875 B.C. Ltd. British Columbia, Canada BST Sub ULC British Columbia, Canada Streamex Exchange Corporation British Columbia, Canada Streamex Capital LLC Delaware Streamex Partners LLC British Columbia, Canada GLDY ServiceCo LLC Delaware Streamex Gold SPV LLC Delaware Streamex Tokenization Holdco SPV LLC De

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

EXHIBIT 32.02 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Christine Plummer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Streamex Corp. on Form 10-K for the fiscal year ended December 31, 2025 f

CERTIFICATION

EXHIBIT 31.01 CERTIFICATION I, Henry McPhie, certify that: 1. I have reviewed this annual report on Form 10-K of Streamex Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the

LOCK-UP AGREEMENT

Exhibit 10.1 LOCK-UP AGREEMENT March 26, 2026 Ladies and Gentlemen: The undersigned irrevocably agrees with Streamex Corp. (the “Company”) that, from the date hereof until the date that is the one (1) year anniversary of the date hereof (such period, the “Restriction Period”) the undersigned will not offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of (or enter into any tran

Streamex Corp. Clarifies and Refutes Inaccurate Claims Regarding Lock-Up Agreements; Co-Founders Morgan Lekstrom & Henry McPhie Enter into Voluntary 1 Year Lock-Up Agreements

Exhibit 99.1 Streamex Corp. Clarifies and Refutes Inaccurate Claims Regarding Lock-Up Agreements; Co-Founders Morgan Lekstrom & Henry McPhie Enter into Voluntary 1 Year Lock-Up Agreements Winter Park, FL – March 27, 2026 – Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX) today issued a statement to clarify and formally refute a series of third-party posts attributed to S&P Capital IQ an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 26, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 26, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State (Commission (I.R.S. Employer of incorporation) File Number) Id

Streamex Corp. Appoints Christine Plummer, Former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer

Exhibit 99.1 Streamex Corp. Appoints Christine Plummer, Former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer WINTER PARK, Fla., March 16, 2026 — Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a technology and infrastructure company focused on the tokenization of commodity real-world assets, today announced the appointment of Christi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 16, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 16, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State (Commission (I.R.S. Employer of incorporation) File Number) Id

SEPARATION AND GENERAL RELEASE AGREEMENT

Exhibit 10.1 SEPARATION AND GENERAL RELEASE AGREEMENT This Separation and General Release Agreement (this “Agreement”) is entered into by and between Ferdinand Groenewald (the “Executive”) and Streamex Corp., a Delaware Corporation (the “Company”). Capitalized terms that are used but not defined herein have the meanings given to them in that certain Employment Agreement between the Executive and t

STREAMEX CORP. CONSULTING AGREEMENT

Exhibit 10.2 STREAMEX CORP. CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is made and entered into March 16, 2026 (the “Effective Date”) by and between Streamex Corp., a Delaware C-corporation with its principal place of business at 2431 Aloma Avenue Suite 243 Winter Park, FL 32792 (the “Company”), and Groenewald Enterprises LLC, a Florida Limited Liability Company (“Consultant

EMPLOYMENT AGREEMENT

Exhibit 10.3 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is dated for reference March 16, 2026, BETWEEN: STREAMEX CORP., a company incorporated under the laws of the State of Delaware and having an office at 2431 Aloma Ave., Suite 243, Winter Park, Florida 32792. (the “Company”) OF THE FIRST PART AND: CHRISTINE PLUMMER, a person with a residence at [address redacted]. (the “Em

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 3, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 3, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State (Commission (I.R.S. Employer of incorporation) File Number) Ide

Streamex Corp. Appoints Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. & Founder and CIO of Hondius Capital Management, to Board of Directors

Exhibit 99.1 Streamex Corp. Appoints Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. & Founder and CIO of Hondius Capital Management, to Board of Directors WINTER PARK, Fla., March 03, 2026 (GLOBE NEWSWIRE) — Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today is excited to announce the appointment

STREAMEX CORP. (Nasdaq: STEX) 2431 Aloma Ave Ste 243, Winter Park, Florida 32792 www.streamex.com (203) 409-5444 [email protected]

Exhibit 10.1 March 3, 2026 To: Shawn Matthews Via email RE: Offer to Join the Board of Directors Dear Shawn, In recognition of the value your skills, expertise, and experience will bring to Streamex Corp. (the “Company”), we are pleased to extend this offer for you to serve as a member of the Company’s Board of Directors (the “Board”). Your appointment will become effective upon your acceptance of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 9, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 9, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State (Commission (I.R.S. Employer of incorporation) File Number)

Streamex Corp. 2,443,750 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-276298 Prospectus Supplement (To Prospectus dated December 17, 2024) Streamex Corp. 2,443,750 Shares of Common Stock On December 11, 2025, Streamex Corp. (the “Company”), pursuant to a Share Purchase Agreement, issued 2,443,750 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share, to Terra Capital Natural Resources Fu

Calculation of Filing Fee Tables Form S-8 (Form Type) Streamex Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Streamex Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Streamex Corp. Technologies, Inc. 2

As filed with the Securities and Exchange Commission on February 13, 2026

As filed with the Securities and Exchange Commission on February 13, 2026 Registration No.

Streamex Corp. (NASDAQ: STEX) Appoints Morgan Lekstrom as Executive Chairman, & Announces Completed Repayment of Convertible Debenture and Cancellation of SEPA

Exhibit 99.1 Streamex Corp. (NASDAQ: STEX) Appoints Morgan Lekstrom as Executive Chairman, & Announces Completed Repayment of Convertible Debenture and Cancellation of SEPA Winter Park, FL – February 9, 2026 – Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today announced that its Co-Founder and Chairman,

Streamex Corp. (NASDAQ: STEX) Appoints Anthony Marciano, Clinical Professor of Finance at NYU Stern to Board of Directors

Exhibit 99.1 Streamex Corp. (NASDAQ: STEX) Appoints Anthony Marciano, Clinical Professor of Finance at NYU Stern to Board of Directors Winter Park, FL, – February 4, 2026 – Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today announced the appointment of Anthony Marciano, Clinical Professor of Finance at N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 3, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 3, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State (Commission (I.R.S. Employer of incorporation) File Number)

STREAMEX CORP. (Nasdaq: STEX) 2431 Aloma Ave Ste 243, Winter Park, Florida 32792 www.streamex.com (203) 409-5444 [email protected]

Exhibit 10.1 Via email: February 3, 2026 To: Anthony Marciano [email protected] RE: Offer to Join the Board of Directors Dear Anthony, In recognition of the value your skills, expertise, and experience will bring to Streamex Corp. (the “Company”), we are pleased to extend this offer for you to serve as a member of the Company’s Board of Directors (the “Board”). Your appointment will become effec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 22, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 22, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State (Commission (I.R.S. Employer of incorporation) File Number)

Streamex Corp. (NASDAQ: STEX) Announces Pricing of $35 Million Public Offering

Exhibit 99.2 Streamex Corp. (NASDAQ: STEX) Announces Pricing of $35 Million Public Offering Winter Park, FL – January 22, 2026 (GLOBE NEWSWIRE) – Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a leader in institutional-grade tokenization of real-world assets and commodity-backed stablecoins, including GLDY, today announced the pricing of its previously announced an underwritten publi

Streamex Corp. (NASDAQ: STEX) Announces Closing of $35 Million Public Offering

Exhibit 99.3 Streamex Corp. (NASDAQ: STEX) Announces Closing of $35 Million Public Offering Winter Park, FL – January 26, 2026 (GLOBE NEWSWIRE) – Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a leader in institutional-grade tokenization of real-world assets and commodity-backed stablecoins, including GLDY, today announced the closing of its previously announced underwritten public o

Streamex Corp. (NASDAQ: STEX) Announces Issuance of Prepayment Notice for Previously Announced Convertible Debenture Financing & Notice of Termination for Standby Equity Purchase Agreement

Exhibit 99.1 Streamex Corp. (NASDAQ: STEX) Announces Issuance of Prepayment Notice for Previously Announced Convertible Debenture Financing & Notice of Termination for Standby Equity Purchase Agreement January 23, 2026 WINTER PARK, Fla., Jan. 23, 2026 (GLOBE NEWSWIRE) — Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a leader in institutional-grade tokenization of commodity assets, to

Streamex Corp. (NASDAQ: STEX) Announces Proposed Public Offering

Exhibit 99.1 Streamex Corp. (NASDAQ: STEX) Announces Proposed Public Offering Winter Park, FL – January 22, 2026 (GLOBE NEWSWIRE) – Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a leader in institutional-grade tokenization of real-world assets and commodity-backed stablecoins, including GLDY, today announced its intention to offer shares of common stock through an underwritten publi

Streamex Corp. (NASDAQ: STEX) Announces Closing of Underwriters’ Over-Allotment Option in Full, Resulting in Gross Proceeds of $40.25 Million

Exhibit 99.4 Streamex Corp. (NASDAQ: STEX) Announces Closing of Underwriters’ Over-Allotment Option in Full, Resulting in Gross Proceeds of $40.25 Million Winter Park, FL – January 27, 2026 (GLOBE NEWSWIRE) – Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a leader in institutional-grade tokenization of real-world assets and commodity-backed stablecoins, including GLDY, today announce

11,666,667 Shares STREAMEX CORP. Common Stock, $0.001 par value per share UNDERWRITING AGREEMENT

Exhibit 1.1 11,666,667 Shares STREAMEX CORP. Common Stock, $0.001 par value per share UNDERWRITING AGREEMENT January 22, 2026 Needham & Company, LLC As Representative of the several Underwriters Needham & Company, LLC 250 Park Avenue, 10th Floor New York, NY 10177 Ladies and Gentlemen: Introductory. Streamex Corp., a Delaware corporation (the “Company”), proposes to issue and sell, pursuant to the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 22, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 22, 2026 Date of Report (Date of earliest event reported) STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State (Commission (I.R.S. Employer of incorporation) File Number)

Streamex Corp. 11,666,667 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-276298 Prospectus Supplement (To Prospectus dated December 17, 2024) Streamex Corp. 11,666,667 Shares of Common Stock We are offering 11,666,667 shares of our common stock, par value $0.001 per share. Our common stock is traded on the Nasdaq Capital Market under the symbol “STEX.” On January 21, 2026, the last reported sale price of our common

Subject to Completion, dated January 22, 2026

The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2025 STREAMEX CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2025 STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of incor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2025 STREAMEX CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2025 STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of incorpo

FOURTH AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2023 LONG-TERM INCENTIVE PLAN

Exhibit 10.1 FOURTH AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2023 LONG-TERM INCENTIVE PLAN This FOURTH AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2023 LONG-TERM INCENTIVE PLAN (this “Amendment”), effective as of December 30, 2025, is made and entered into by Streamex Corp. (formerly BioSig Technologies, Inc.), a Delaware corporation (the “Company”). Terms used in this Amendment with initial capi

AMENDMENT NO. 4 TO SECURED CONVERTIBLE DEBENTURE PURCHASE AGREEMENT

Exhibit 10.1 AMENDMENT NO. 4 TO SECURED CONVERTIBLE DEBENTURE PURCHASE AGREEMENT This AMENDMENT NO. 4 TO SECURED CONVERTIBLE DEBENTURE PURCHASE AGREEMENT (this “Amendment”) is made and entered into as of December 17, 2025, by and between STREAMEX CORP. (f/k/a/ BIOSIG TECHNOLOGIES, INC.), a company incorporated under the laws of the State of Delaware, with principal executive offices located at 243

EX-99.1

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2025 STREAMEX CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2025 STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of incorpo

Streamex Corp. (NASDAQ: STEX) Acquires 9.9% Strategic Equity Stake in Royalty and Streaming Firm Empress Royalty Corp. Through a Premium Priced Share-for-Share Transaction at US$5.00 STEX with a Leading Institutional Investment Firm

Exhibit 99.1 Streamex Corp. (NASDAQ: STEX) Acquires 9.9% Strategic Equity Stake in Royalty and Streaming Firm Empress Royalty Corp. Through a Premium Priced Share-for-Share Transaction at US$5.00 STEX with a Leading Institutional Investment Firm LOS ANGELES, CA – December 11, 2025 — Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a leader in institutional-grade tokenization and real-w

EX-10.1

Exhibit 10.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2025 STREAMEX CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2025 STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of incorpo

As filed with the U.S. Securities and Exchange Commission on December 8, 2025

As filed with the U.S. Securities and Exchange Commission on December 8, 2025 Registration No. 333-291659 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 26-4333375 (State or other jurisdiction of incorporation or

VIA EDGAR

VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance One Station Place 100 F Street N.E. Washington, D.C. 20549-7010 December 8, 2025 Re: Streamex Corp. Registration Statement on Form S-3, as amended (No. 333-291659) Ladies and Gentlemen: The undersigned registrant hereby requests that the effectiveness of the above-captioned Registration Statement on Form S-3 initiall

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Streamex Corp. (NASDAQ: STEX) Announces Appointment of Kevin Gopaul, Global Financial Executive and ETF Pioneer to Its Board of Directors

Exhibit 99.1 Streamex Corp. (NASDAQ: STEX) Announces Appointment of Kevin Gopaul, Global Financial Executive and ETF Pioneer to Its Board of Directors LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) — Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today announced the appointment of Kevin Gopaul, global financi

STREAMEX CORP. (Nasdaq: STEX) 2431 Aloma Ave Ste 243, Winter Park, Florida 32792 www.streamex.com (203) 409-5444 [email protected]

Exhibit 10.1 Via email: Nov 17, 2025 To: Kevin Gopaul [email protected] RE: Offer to Join the Board of Directors Dear Kevin, In recognition of the value your skills, expertise, and experience will bring to Streamex Corp. (the “Company”), we are pleased to extend this offer for you to serve as a member of the Company’s Board of Directors (the “Board”). Your appointment will become effective u

CHAIRMAN OF THE BOARD AGREEMENT STREAMEX CORP.

Exhibit 10.4 CHAIRMAN OF THE BOARD AGREEMENT STREAMEX CORP. This Chairman of the Board Agreement (this “Agreement”) is entered into as of November 18, 2025 (the “Effective Date”), by and between Streamex Corp., a Delaware corporation (the “Company”), and Morgan Lekstrom (the “Chairman”). 1. Appointment and Duties (a) The Company hereby appoints the Chairman to serve as Chairman of the Board of Dir

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2025 STREAMEX CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2025 STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of incorpo

ELEVENTH CERTIFICATE OF AMENDMENT ELEVENTH CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF STREAMEX CORP.

Exhibit 3.1 ELEVENTH CERTIFICATE OF AMENDMENT ELEVENTH CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF STREAMEX CORP. Streamex Corp. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware hereby certifies as follows: 1. The name of the Corporation is Streamex Corp. The Corporation’s original Certificate of Incorporatio

Employment Agreement

Exhibit 10.2 Employment Agreement This Employment Agreement (the “Agreement”) is made and entered into as of November 18, 2025, by and between Henry McPhie (the “Executive”) and Streamex Corp., a Delaware Corporation (the “Company”). WHEREAS, the Company desires to employ the Executive on the terms and conditions set forth herein; and WHEREAS, the Executive desires to be employed by the Company on

Calculation of Filing Fee Tables Registration Statement on Form S-3 (Form Type) Streamex Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-3 (Form Type) Streamex Corp.

Employment Agreement

Exhibit 10.3 Employment Agreement This Employment Agreement (the “Agreement”) is made and entered into as of November 18, 2025, by and between Ferdinand Groenewald (the “Executive”) and Streamex Corp., a Delaware corporation (the “Company”). WHEREAS, the Company desires to employ the Executive on the terms and conditions set forth herein; and WHEREAS, the Executive desires to be employed by the Co

As filed with the U.S. Securities and Exchange Commission on November 19, 2025

As filed with the U.S. Securities and Exchange Commission on November 19, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 26-4333375 (State or other jurisdiction of incorporation or organization) (I.R.S. E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 STREAMEX

1CANADIAN GUARANTEE AND SECURITY AGREEMENT dated as of November 4, 2025, STREAMEX corp., the other Persons party hereto from time to time as Grantors, YA II PN, LTD., as Collateral Agent

Exhibit 10.3 1CANADIAN GUARANTEE AND SECURITY AGREEMENT dated as of November 4, 2025, among STREAMEX corp., and the other Persons party hereto from time to time as Grantors, and YA II PN, LTD., as Collateral Agent 1 NTD: This Agreement remains subject to review and comment in all respects (including, without limitation, by RS) and alignment with final U.S. Guaranty and Security Agreement. CANADIAN

STREAMEX CORP. (F/K/A BIOSIG TECHNOLOGIES, INC.) Form of Secured Convertible Debenture

Exhibit 4.1 NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXC

Streamex Corp. (NASDAQ: STEX) Announces Gold Bullion Purchases & Closing of Initial USD $25,000,000 Tranche of the Previously Announced Financing; All Net Proceeds Deployed into Physical Gold Bullion USD $25,000,000 tranche from the previously announ

Exhibit 99.1 Streamex Corp. (NASDAQ: STEX) Announces Gold Bullion Purchases & Closing of Initial USD $25,000,000 Tranche of the Previously Announced Financing; All Net Proceeds Deployed into Physical Gold Bullion USD $25,000,000 tranche from the previously announced July 2025 financing initiates Streamex’s physical gold bullion purchases as per the Company’s stated business plan and accelerates it

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 STREAMEX CORP. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of incorpor

AMENDMENT NO. 3 TO SECURED CONVERTIBLE DEBENTURE PURCHASE AGREEMENT

Exhibit 10.1 AMENDMENT NO. 3 TO SECURED CONVERTIBLE DEBENTURE PURCHASE AGREEMENT This AMENDMENT NO. 3 TO SECURED CONVERTIBLE DEBENTURE PURCHASE AGREEMENT (this “Amendment”) is made and entered into as of November 4, 2025, by and between STREAMEX CORP. (f/k/a/ BIOSIG TECHNOLOGIES, INC.), a company incorporated under the laws of the State of Delaware, with principal executive offices located at 2431

REGISTRATION RIGHTS AGREEMENT

Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 4, 2025, is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and STREAMEX CORP. (F/K/A BIOSIG TECHNOLOGIES, INC.), a company incorporated under the laws of the State of Delaware (the “Company”). The Investor and the Company may be refer

GUARANTY AND SECURITY AGREEMENT dated as of November 4, 2025, STREAMEX CORP., the other Persons party hereto from time to time as Grantors, YA II PN, LTD., as Collateral Agent GUARANTY AND SECURITY AGREEMENT

Exhibit 10.2 GUARANTY AND SECURITY AGREEMENT dated as of November 4, 2025, among STREAMEX CORP., and the other Persons party hereto from time to time as Grantors, and YA II PN, LTD., as Collateral Agent GUARANTY AND SECURITY AGREEMENT This GUARANTY AND SECURITY AGREEMENT, dated as of November 4, 2025 (as amended, amended and restated, supplemented or otherwise modified from time to time, this “Agr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 STREAMEX CORP. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of incorpor

EX-99.1

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Streamex Corp. (NASDAQ: STEX) Announces Nasdaq Approval for Continued Listing on Nasdaq Capital Market & Shareholder Meeting on November 4, 2025

Exhibit 99.1 Streamex Corp. (NASDAQ: STEX) Announces Nasdaq Approval for Continued Listing on Nasdaq Capital Market & Shareholder Meeting on November 4, 2025 Los Angeles, CA – October 30, 2025 (GLOBE NEWSWIRE) – Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), an institutional commodity tokenization company, today announced that it has received formal approval from Nasdaq for continued

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025 STREAMEX CORP. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025 STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of incorpor

AMENDMENT NO. 2 TO SECURED CONVERTIBLE DEBENTURE PURCHASE AGREEMENT

Exhibit 10.1 AMENDMENT NO. 2 TO SECURED CONVERTIBLE DEBENTURE PURCHASE AGREEMENT This AMENDMENT NO. 2 TO SECURED CONVERTIBLE DEBENTURE PURCHASE AGREEMENT (this “Amendment”) is made and entered into as of October 28, 2025, by and between STREAMEX CORP. (f/k/a/ BIOSIG TECHNOLOGIES, INC.), a company incorporated under the laws of the State of Delaware, with principal executive offices located at 2431

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2025 STREAMEX CORP. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2025 STREAMEX CORP. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of incorpor

As filed with the Securities and Exchange Commission on October 3, 2025

As filed with the Securities and Exchange Commission on October 3, 2025 Registration No.

Calculation of Filing Fee Tables Form S-8 (Form Type) Streamex Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Fees Previously Paid

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Streamex Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Fees Previously Paid Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Streamex Corp.

CERTIFICATE OF TENTH AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOSIG TECHNOLOGIES, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware

Exhibit 3.1 CERTIFICATE OF TENTH AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOSIG TECHNOLOGIES, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware BioSig Technologies, Inc. (hereinafter called the “Corporation”), organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, does he

BioSig Technologies, Inc. Announces Corporate Rebrand to Streamex Corp. Strategic Rebranding to Focus on Expanded Business Model and Growth Strategy. New Ticker Symbol “STEX”.

Exhibit 99.1 BioSig Technologies, Inc. Announces Corporate Rebrand to Streamex Corp. Strategic Rebranding to Focus on Expanded Business Model and Growth Strategy. New Ticker Symbol “STEX”. LOS ANGELES & VANCOUVER, British Columbia - September 10, 2025 - - BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig”), which recently merged with Streamex Exchange Corporation (“Streamex”) (together, “BSGM” or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 10, 2025 BioSig Technol

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 10, 2025 BioSig Technologies, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-38659 26-4333375 (State or other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Tokenized Yield Partnership Agreement BioSig Technologies, Inc. d/b/a StreamEx Monetary Metals & Co. dated as of September 8, 2025 Tokenized Yield Partnership Agreement

Exhibit 10.1 Tokenized Yield Partnership Agreement between BioSig Technologies, Inc. d/b/a StreamEx and Monetary Metals & Co. dated as of September 8, 2025 Tokenized Yield Partnership Agreement This Tokenized Yield Partnership Agreement dated as of September 8, 2025 (this “Agreement”), is entered into between BioSig Technologies, Inc. d/b/a StreamEx, a Delaware Corporation (“StreamEx”), and Moneta

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2025 BioSig Technolo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer

September 8, 2025

Exhibit 99.1 September 8, 2025 Streamex Exchange Corp NASDAQ-BSGM Creates a Tokenized Yield-Bearing Gold Product Generating up-to 4% through Exclusive Partnership with Monetary Metals Partnership unlocks exclusive tokenization rights, a four percent (4%) annual yield target on physical bullion, revenue share tied to leasing volumes and the creation of a groundbreaking institutionalized asset provi

THIRD AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2023 LONG-TERM INCENTIVE PLAN

Exhibit 10.1 THIRD AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2023 LONG-TERM INCENTIVE PLAN This THIRD AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2023 LONG-TERM INCENTIVE PLAN (this “Amendment”), effective as of September 5, 2025, is made and entered into by BioSig Technologies, Inc., a Delaware corporation (the “Company”). Terms used in this Amendment with initial capital letters that are not oth

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2025 BioSig Technolo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer

NINTH CERTIFICATE OF AMENDMENT NINTH CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOSIG TECHNOLOGIES, INC.

Exhibit 3.1 NINTH CERTIFICATE OF AMENDMENT NINTH CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOSIG TECHNOLOGIES, INC. BioSig Technologies, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware hereby certifies as follows: 1. The name of the Corporation is BioSig Technologies, Inc. The Corporation’s original

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 3)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 3) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

Biosig Technologies, Inc. & Streamex Announce Closing of $15 Million Public Offering Offering Structured to Accelerate Streamex’s Operational Build-Out, Strategically Allocated with No Warrants

Exhibit 99.3 Biosig Technologies, Inc. & Streamex Announce Closing of $15 Million Public Offering Offering Structured to Accelerate Streamex’s Operational Build-Out, Strategically Allocated with No Warrants LOS ANGELES, USA - August 15, 2025 — BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), a gold tokeniza

BioSig Technologies Inc. Announces Pricing of $15 Million Public Offering

Exhibit 99.2 BioSig Technologies Inc. Announces Pricing of $15 Million Public Offering Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), today announced the pricing of its previously announced underwritten public offering of 3,852,149 shares of common stock a

BioSig Technologies Inc. Announces Proposed Public Offering

Exhibit 99.1 BioSig Technologies Inc. Announces Proposed Public Offering Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (“BioSig” or the “Company”) which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM) today announced its intention to offer shares of common stock (or pre-funded warrants in lieu thereof) through an underwritten public offe

Form of Secured Convertible Debenture

Exhibit 10.8 NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EX

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2025 BioSig Technologi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2025 BioSig Technologies, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-38659 26-4333375 (State or other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

Underwriting Agreement, dated as of August 13, 2025, by and among the Company, Clear Street LLC and Needham & Company.

Exhibit 1.1 Certain personally identifiable information has been omitted from this exhibit pursuant to item 601(a)(6) of Regulation S-K. [***] indicates that information has been redacted. 3,852,149 Shares BIOSIG TECHNOLOGIES, INC. Common Stock, $0.001 par value per share UNDERWRITING AGREEMENT August 13, 2025 Clear Street LLC Needham & Company, LLC As Representatives of the several Underwriters C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 BIOSIG TECHNO

BioSig Technologies, Inc. 3,852,149 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-276298 Prospectus Supplement (To Prospectus dated December 17, 2024) BioSig Technologies, Inc. 3,852,149 Shares of Common Stock We are offering 3,852,149 shares of our common stock, par value $0.001 per share. Our common stock is traded on the Nasdaq Capital Market under the symbol “BSGM.” On August 13, 2025, the last reported sale price of our

Subject to Completion, dated August 13, 2025

The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2025 BioSig Technologi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2025 BioSig Technologies, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-38659 26-4333375 (State or other Jurisdiction of Incorporation) (Commissi

Amendment to Secured Convertible Debenture Purchase Agreement, dated as of August 13, 2025, between the Company and YA II PN, Ltd.

Exhibit 10.1 AMENDMENT NO. 1 TO SECURED CONVERTIBLE DEBENTURE PURCHASE AGREEMENT This AMENDMENT NO. 1 TO SECURED CONVERTIBLE DEBENTURE PURCHASE AGREEMENT (this “Amendment”) is made and entered into as of August 13, 2025, by and between BIOSIG TECHNOLOGIES, INC., a company incorporated under the laws of the State of Delaware, with principal executive offices located at 12424 Wilshire Blvd. Suite 74

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

BIOSIG TECHNOLOGIES, INC. UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENTS OF COMPREHENSIVE LOSS FOR THE THREE MONTHS ENDED MARCH 31, 2025 (In Thousands, Except Par Value and Share Amounts)

Exhibit 99.3 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION The following unaudited pro forma combined financial information has been prepared in accordance with Article 11 of Regulation S-X under the Securities Act of 1933, as amended and presents the pro forma effects of the acquisition (such transaction, the “Acquisition”) by BioSig Technologies, Inc., a Delaware corporation (“BioSig” or th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 27, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 27, 2025 March 31, 2025 BioSig Technologies, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-38659 26-4333375 (State or other Jurisdic

INFORMATION ABOUT STREAMEX AND THE SHARE EXCHANGE

Exhibit 99.1 INFORMATION ABOUT STREAMEX AND THE SHARE EXCHANGE The below is an overview of Streamex’s business and certain other information about Streamex that may be relevant to investors. For purposes of this section the words “we,” “our,” “us,” “Streamex” and the “Company” refers to Streamex. Overview Streamex Exchange Corporation (the “Company” or “Streamex”) was incorporated on April 5, 2024

Financial Statements For the period ended December 31, 2024 Expressed in Canadian Dollars

Exhibit 99.2 Financial Statements For the period ended December 31, 2024 Expressed in Canadian Dollars PAGE REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 3 FINANCIAL STATEMENTS Balance Sheet 4 Statement of Loss and Comprehensive Loss 5 Statement of Changes in Stockholders’ Equity 6 Statement of Cash Flows 7 Notes to the Financial Statements 8 2 Report of Independent Registered Public Acc

Secured Convertible Debenture Purchase Agreement, dated as of July 7, 2025, between the Company and YA II PN, Ltd.

Exhibit 10.1 SECURED CONVERTIBLE DEBENTURE PURCHASE AGREEMENT THIS SECURED CONVERTIBLE DEBENTURE PURCHASE AGREEMENT (this “Agreement”), dated as of July 7, 2025, is between BIOSIG TECHNOLOGIES, INC., a company incorporated under the laws of the State of Delaware, with principal executive offices located at 12424 Wilshire Blvd. Suite 745, Los Angeles, CA 90025 (the “Company”), and YA II PN, Ltd. (t

Standby Equity Purchase Agreement, dated as of July 7, 2025, between Company and YA II PN, Ltd.

Exhibit 10.3 STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of July 7, 2025, is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and BioSig Technologies, Inc., a company incorporated under the laws of the State of Delaware (the “Company”). The Investor and the Company may be referred to herein indivi

BioSig Technologies, Inc. and Streamex Exchange Corporation Announce Definitive Agreements for up to $1,100,000,000 ($1.1B USD) in Growth Financing to Launch Gold Backed Treasury Management Strategy and to Rapidly Expand RWA Tokenization for the Comm

Exhibit 99.1 BioSig Technologies, Inc. and Streamex Exchange Corporation Announce Definitive Agreements for up to $1,100,000,000 ($1.1B USD) in Growth Financing to Launch Gold Backed Treasury Management Strategy and to Rapidly Expand RWA Tokenization for the Commodities Markets ● BioSig Technologies, Inc. (Nasdaq: BSGM), which recently merged with Streamex Exchange Corporation (“Streamex”) to beco

Form of Lock-up Agreement

Exhibit 10.2 FORM OF LOCK-UP LETTER AGREEMENT [], 2025 CANTOR FITZGERALD & CO. 110 East 59th Street, 6th Floor New York, NY 10022 CLEAR STREET LLC 4 World Trade Center, Floor 45 New York, NY 10007 RE: PROPOSED PRIVATE PLACEMENT BY BIOSIG TECHNOLOGIES, INC. Ladies and Gentlemen: The undersigned understands that BioSig Technologies, Inc., a Delaware corporation (the “Company”), is entering into a Se

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 7, 2025 BioSig Technologies, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-38659 26-4333375 (State or other Jurisdiction of Incorporation) (Commission

Form of Registration Rights Agreement, by and between Company and YA II PN, Ltd.

Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July [ ], 2025, is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and BIOSIG TECHNOLOGIES, INC., a company incorporated under the laws of the State of Delaware (the “Company”). The Investor and the Company may be referred to herein individuall

Streamex and BioSig Announce the Successful Closing of Share Exchange Transaction and Executive Leadership Changes Bringing a First-Mover Real World Asset Tokenization Company to the Nasdaq

Exhibit 99.1 Streamex and BioSig Announce the Successful Closing of Share Exchange Transaction and Executive Leadership Changes Bringing a First-Mover Real World Asset Tokenization Company to the Nasdaq May 28, 2025 Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig”) and Streamex Exchange Corporation (“Streamex”), collectively refe

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 27, 2025 BioSig Technologies, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-38659 26-4333375 (State or other Jurisdiction of Incorporation) (Commission

First Amendment to Share Purchase Agreement, dated May 27, 2025, by and among BioSig Technologies, Inc., Streamex Exchange Corporation, BST Sub ULC and 1540875 B.C. Ltd.

Exhibit 10.2 FIRST AMENDMENT TO SHARE PURCHASE AGREEMENT This First Amendment (this “First Amendment”) to the Share Purchase Agreement (as defined below) is made and entered into as of May 27, 2025, by BIOSIG TECHNOLOGIES, INC., a Delaware corporation (“Parent”), BST SUB ULC, an unlimited liability company organized under the laws of the Province of British Columbia and a wholly-owned subsidiary o

Form of Finder Agreement

Exhibit 10.1 FORM OF FINDER AGREEMENT This FINDER AGREEMENT (this “Agreement”) is made and entered into as of this [●] day of May, 2025, by and among [●] (“Finder”), Streamex Exchange Corp. (the “Company”) and BioSig Technologies, Inc. (the “Target Company” and together with Finder and the Company, the “Parties”). R E C I T A L S A. The Company desires an introduction to the management of the Targ

Form of Exchange Rights Agreement

Exhibit 10.2 EXCHANGE RIGHTS AGREEMENT BY AND AMONG BIOSIG TECHNOLOGIES, INC. BST SUB ULC 1540875 B.C. LTD. AND 1540873 B.C. LTD. DATED AS OF [], 2025 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS AND INTERPRETATION 5 1.1 Definitions 5 1.2 Interpretation Not Affected by Headings 8 1.3 Number, Gender, etc. 8 1.4 Date for any Action 8 1.5 Currency 8 1.6 Statutes 8 1.7 Exhibits 9 ARTICLE 2 9 TRUST 9 2.1 Es

Form of First Amendment to the Executive Employment Agreement

Exhibit 10.4 First AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This First AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”), entered into as of the Effective Time (as defined below), by and between Anthony Amato (“Executive”) and BioSig Technologies Inc., a Delaware corporation (the “Company”), for the purpose of amending that certain Executive Employment Agreement, dated as of August

Share Purchase Agreement, dated as of May 23, 2025, by and among BioSig Technologies, Inc., Streamex Exchange Corporation, BST Sub ULC, 1540875 B.C. Ltd., the shareholders of Streamex Exchange Corporation, and 1540873 B.C. Ltd., as trustee

Exhibit 2.1 SHARE PURCHASE AGREEMENT by and among BIOSIG TECHNOLOGIES, INC., a Delaware corporation; BST SUB ULC, a British Columbia, Canada unlimited liability company; 1540875 B.C. LTD., a British Columbia, Canada corporation; STREAMEX EXCHANGE CORPORATION, a British Columbia, Canada corporation; each shareholder of STREAMEX EXCHANGE CORPORATION; and 1540873 B.C. LTD., as Trustee of the trust fo

Form of Certificate of Designation of Special Voting Stock of BioSig Technologies, Inc.

Exhibit 3.1 BIOSIG TECHNOLOGIES, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SPECIAL VOTING PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of BioSig Technologies, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the Board o

BioSig Technologies, Inc. Signs Definitive Share Exchange Agreement with Streamex Exchange Corp. to Launch First-Mover Real-World Asset (RWA) Tokenization Company Bringing Commodity Markets On-Chain.

Exhibit 99.1 BioSig Technologies, Inc. Signs Definitive Share Exchange Agreement with Streamex Exchange Corp. to Launch First-Mover Real-World Asset (RWA) Tokenization Company Bringing Commodity Markets On-Chain. May 23, 2025 Los Angeles, CA and Vancouver, BC, May 23, 2025 (GLOBE NEWSWIRE) – BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company, today a

Form of Letter Agreement

Exhibit 10.5 , 2025 Re: Letter Agreement - Right to Place This letter agreement (“Letter Agreement”) sets forth the terms of the mutual understanding and agreement of BioSig Technologies, Inc. (“BSGM”) and Anthony Amato (“Amato”) with regard to BSGM’s Right to Place (as defined below). In consideration of the foregoing and for other good and valuable consideration, including the amendment of that

Form of Voting Agreement

Exhibit 10.1 FORM OF PARENT STOCKHOLDER VOTING AGREEMENT BIOSIG TECHNOLOGIES, INC. VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”), dated as of [], 2025, is made by and among BioSig Technologies, Inc., a Delaware corporation (“Parent”), Streamex Exchange Corporation, a corporation organized under the laws of the Province of British Columbia (the “Company”), and the undersigned holder (“S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 23, 2025 BioSig Technologies,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 23, 2025 BioSig Technologies, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-38659 26-4333375 (State or other Jurisdiction of Incorporation) (Commission

Form of Support Agreement

Exhibit 10.3 SUPPORT AGREEMENT among BIOSIG TECHNOLOGIES, INC. and BST SUB ULC AND 1540875 B.C. LTD. DATED as of [], 2025 Table of Contents Article 1 DEFINITIONS AND INTERPRETATION 3 1.1 Definitions 3 1.2 Interpretation Not Affected by Headings. 4 1.3 Number and Gender. 4 1.4 Date of any Action. 4 1.5 Statutes. 4 Article 2 COVENANTS OF PARENT AND EXCHANGECO 5 2.1 Covenants Regarding Exchangeable S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 BIOSIG TECHN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Perio

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commission

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of in

Figure 1: The Streamex Ecosystem Figure 2: The Streamex Platform

Exhibit 99.2 BioSig Enters into an LOI to Merge with Streamex Exchange Corp. Creating a Publicly Listed Real-World Asset Tokenization Company Led by Seasoned Industry Executives Los Angeles, CA, May 5, 2025 (GLOBE NEWSWIRE) – BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company is pleased to announce it has entered into a Letter of Intent (“LOI”) to en

Letter of Intent

Exhibit 99.1 CONFIDENTIAL Letter of Intent May 5, 2025 BioSig Technologies, Inc. Anthony Amato Chief Executive Officer 12424 Wilshire Blvd., Ste. 745 Los Angeles, CA 90025 RE: Proposed Merger Transaction between BioSig Technologies, Inc. and Streamex Exchange Corporation Dear Mr. Amato, This Letter of Intent (this “LOI”) summarizes the principal terms relating to a proposed merger or other busines

Letter from Marcum LLP dated April 30, 2025

Exhibit 16 April 30, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by BioSig Technologies, Inc. under Item 4.01 of its Form 8-K dated April 30, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of BioSig Technologies, Inc. cont

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 BioSig Technologie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 BioSig Technologie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commissio

Common Stock Purchase Warrant of ViralClear Pharmaceuticals, Inc., dated November 20, 2019, issued to Mayo Clinic Ventures

Exhibit 4.42 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

EXHIBIT 32.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Ferdinand Groenewald, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of BioSig Technologies, Inc. on Form 10-K for the fiscal year ended December

Certification of Chief Executive Officer and Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

EXHIBIT 31.02 CERTIFICATION I, Ferdinand Groenewald, certify that: 1. I have reviewed this annual report on Form 10-K of BioSig Technologies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading w

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 ☐ TRANSITION REPORT UNDER SECTON 13.0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 Or ☐ TRANSITION REPORT UNDER SECTON 13.08 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38659 BIOSIG TECHNOLOGIES, INC. (Exact

Certification of Chief Executive Officer and Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

EXHIBIT 31.01 CERTIFICATION I, Anthony Amato, certify that: 1. I have reviewed this annual report on Form 10-K of BioSig Technologies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with res

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commissio

Exhibit 4.1

EXHIBIT 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of April 14, 2025, BioSig Technologies, Inc., a Delaware corporation (“we,” “our” and the “Company”) has our common stock, par value $0.001 per share registered under Section 12 of the Securities Exchange Act of 1934, as amended. The foregoing description is intended as a summary and i

Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

EXHIBIT 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Anthony Amato, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of BioSig Technologies, Inc. on Form 10-K for the fiscal year ended December 31, 202

Insider Trading Policy

Exhibit 19.1 BIOSIG TECHNOLOGIES, INC. Insider Trading COMPLIANCE POLICY BioSig Technologies, Inc. (the “Company”) prohibits: ● insider trading in the Company’s securities (“Securities”)1; and ● the unauthorized disclosure of the Company’s confidential information that might enable others to engage in insider trading in the Securities. The Company adopted this Insider Trading Compliance Policy to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 BioSig Technologie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commissio

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commission

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commission

Form of Securities Purchase Agreement

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 5, 2025 between BioSig Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condition

Form of Common Stock Purchase Warrant dated March 5, 2025 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on March 5, 2025)

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Equity Subscription Agreement, dated February 28, 2025, between the Company and Lind Global Fund III, LP (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on March 3, 2025)

Exhibit 10.1 EQUITY SUBSCRIPTION AGREEMENT THIS EQUITY SUBSCRIPTION AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of February 28, 2025, is made by and between Lind Global Fund III, LP, a Delaware limited partnership (the “Investor”), and BioSig Technologies, Inc., a Delaware corporation (the “Company”). The Investor and the Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 BioSig Technolo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commis

Filing Fee Table*

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) BioSig Technologies, Inc.

As filed with the Securities and Exchange Commission on January 13, 2025

As filed with the Securities and Exchange Commission on January 13, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2024 BioSig Technolo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer

BioSig Technologies, Inc. Second Amendment to the BioSig Technologies, Inc. 2023 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to Form 8-K filed on December 31, 2024)

Exhibit 10.1 SECOND AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2023 LONG-TERM INCENTIVE PLAN This SECOND AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2023 LONG-TERM INCENTIVE PLAN (this “Amendment”), effective as of December 31, 2024, is made and entered into by BioSig Technologies, Inc., a Delaware corporation (the “Company”). Terms used in this Amendment with initial capital letters that are not o

BioSig Technologies, Inc. Up to $8,500,000 of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-276298 Prospectus Supplement (To Prospectus Dated December 17, 2024) BioSig Technologies, Inc. Up to $8,500,000 of Common Stock We have entered into an At The Market Offering Agreement, dated December 18, 2024 (the “Sales Agreement”), with H.C. Wainwright & Co., LLC, as sales agent or principal (“Wainwright” or the “sales agent”) relating to th

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commis

At The Market Offering Agreement, dated December 18, 2024, by and between BioSig Technologies, Inc. and H.C. Wainwright & Co., LLC

Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT December 18, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue, 3rd Floor New York, New York 10022 Ladies and Gentlemen: BioSig Technologies, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow,

BioSig Technologies, Inc. 12424 Wilshire Blvd, Suite 745 Los Angeles, California 90025

BioSig Technologies, Inc. 12424 Wilshire Blvd, Suite 745 Los Angeles, California 90025 December 13, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Attention: Robert Augustin Re: BioSig Technologies, Inc. Registration Statement on Form S-3 File No. 333-276298 (the “Registration Statement”) Request for Acceleration Ladies and Gentlemen:

Filing Fee Exhibit

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) BioSig Technologies, Inc.

As filed with the U.S. Securities and Exchange Commission on December 9, 2024

As filed with the U.S. Securities and Exchange Commission on December 9, 2024 Registration No. 333-276298 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 26-4333375 (State or other jurisdi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 BIOSIG T

BSGM / BioSig Technologies, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

SC 13G/A 1 armistice-bsgm093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* BioSig Technologies, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09073N300 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) C

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commis

BioSig Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Exhibit 99.1 BioSig Regains Compliance with Nasdaq’s Minimum Bid Price Requirement Los Angeles, CA, November 13, 2024 —BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or “Company”), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced that it has received notice from the Nasdaq Listing Qualifications staff (“Nasdaq”)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commiss

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commiss

Executive Employment Agreement, dated September 11, 2024, by and between BioSig Technologies, Inc. and Anthony Amato (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on September 13, 2024)

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), made and entered into this 1st day of August 2024 (the “Effective Date”), by and between BioSig Technologies Inc. (the “Company”), and Anthony Amato (“Executive”). WHEREAS, the Company wishes to continually employ Executive as its Chief Executive Officer (“CEO”); and WH

Form of Restricted Stock Award Agreement

Exhibit 10.2 BIOSIG TECHNOLOGIES, INC. FORM OF RESTRICTED STOCK AWARD AGREEMENT 1. Grant of Award. Pursuant to the terms of this Restricted Stock Award Agreement (this “Agreement”) and in exchange for services rendered to BioSig Technologies, Inc., a Delaware corporation (the “Company”), the Company hereby grants to (the “Grantee”) an award of shares of restricted stock (the “Awarded Shares”). The

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employe

Form of Stock Option Agreement (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K filed with the SEC on September 13, 2024)

Exhibit 10.3 BIOSIG TECHNOLOGIES, INC. FORM OF STOCK OPTION AGREEMENT I. NOTICE OF STOCK OPTION GRANT Name: The undersigned Optionee has been granted this Option (defined below) to purchase common stock (“Common Stock”) of BioSig Technologies, a Delaware corporation, or any successor thereto (the “Company”), subject to the terms and conditions of this BioSig Technologies, Inc. Stock Option Agreeme

Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

EXHIBIT 31.2 CERTIFICATION I, Ferdinand Groenewald, certify that: 1. I have reviewed this quarterly report on Form 10-Q of BioSig Technologies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading

Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

EXHIBIT 32.1 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Anthony Amato, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of BioSig Technologies, Inc. on Form 10-Q for the fis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 BIOSIG TECHNO

Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

EXHIBIT 31.1 CERTIFICATION I, Anthony Amato, certify that: 1. I have reviewed this quarterly report on Form 10-Q of BioSig Technologies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with r

PROSPECTUS BioSig Technologies, Inc. 1,680,631 Shares of Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-280525 PROSPECTUS BioSig Technologies, Inc. 1,680,631 Shares of Common Stock This prospectus relates to the resale by the selling stockholders named in this prospectus from time to time of up to 1,680,631 shares of our common stock, par value $0.001 per share, issuable upon the exercise of outstanding warrants issued on May 30, 2024, pursuant t

July 29, 2024

July 29, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F.

As filed with the Securities and Exchange Commission on July 23, 2024

As filed with the Securities and Exchange Commission on July 23, 2024 Registration No.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commission

Engagement Agreement between BioSig Technologies, Inc. and H.C. Wainwright, dated May 29, 2024

Exhibit 10.26 Execution Version May 29, 2024 STRICTLY CONFIDENTIAL BioSig Technologies, Inc. 55 Greens Farms Road, 1st Floor Westport, Connecticut 06880 Attn: Anthony Amato, Principal Executive Officer Dear Mr. Amato: This letter agreement (this “Agreement”) constitutes the agreement between BioSig Technologies, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright sh

BioSig Technologies, Inc. 12424 Wilshire Blvd Suite 745 Los Angeles, CA 90025

BioSig Technologies, Inc. 12424 Wilshire Blvd Suite 745 Los Angeles, CA 90025 July 23, 2024 VIA EDGAR Division of Corporation Finance Office of Industrial Applications and Services United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Aja Eiden Katherine Bagley Re: BioSig Technologies, Inc. Registration Statement on Form S-1 Filed June 27, 2024 File

LETTER

July 11, 2024 Anthony Amato Chief Executive Officer BioSig Technologies, Inc. 55 Greens Farms Road, 1st Floor Westport, CT 06880 Re: BioSig Technologies, Inc. Registration Statement on Form S-1 Filed June 27, 2024 File No. 333-280525 Dear Anthony Amato: We have conducted a limited review of your registration statement and have the following comments. Please respond to this letter by amending your

As filed with the Securities and Exchange Commission on June 27, 2024

As filed with the Securities and Exchange Commission on June 27, 2024 Registration No.

Calculation of Filing Fees Table

EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) BioSig Technologies, Inc.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commission

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of

BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer

Exhibit 99.1 BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer WESTPORT, CT, June 10, 2024 —BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or “the Company”), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of i

1,570,683 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-251859 PROSPECTUS SUPPLEMENT (To the Prospectus Dated January 12, 2021) 1,570,683 Shares of Common Stock We are offering 1,570,683 shares of our common stock, $0.001 par value per share, at a purchase price of $1.91 per share of common stock (the “common stock”) directly to institutional investors pursuant to this prospectus supplement and the

Form of Common Stock Purchase Warrant dated May 30, 2024 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on May 30, 2024)

Exhibit 4.1 EXHIBIT A-1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFEC

Entry into a Material Definitive Agreement, Other Events, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of i

BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Exhibit 99.2 BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Westport, CT, May 30, 2024 — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced

Form of Placement Agent Common Stock Purchase Warrant dated May 30, 2024 (incorporated by reference to Exhibit 4.2 to the Form 8-K filed on May 30, 2024)

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Securities Purchase Agreement dated May 30, 2024 (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on May 30, 2024

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 29, 2024, between BioSig Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions

BioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Exhibit 99.1 BioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Westport, CT, May 30, 2024 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it has entered into definiti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 BioSig Technologies,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of i

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of i

Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

EXHIBIT 31.02 CERTIFICATION I, Frederick D. Hrkac, certify that: 1. I have reviewed this quarterly report on Form 10-Q of BioSig Technologies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading

Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

EXHIBIT 32.01 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Anthony Amato, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of BioSig Technologies, Inc. on Form 10-Q for the fi

Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

EXHIBIT 31.01 CERTIFICATION I, Anthony Amato, certify that: 1. I have reviewed this quarterly report on Form 10-Q of BioSig Technologies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 BIOSIG TECHN

SEC FILE NUMBER

OMB APPROVAL UNITED STATES OMB Number: 3235-0058 SECURITIES AND EXCHANGE COMMISSION Expires: April 30, 2025 Washington, D.

BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent

Exhibit 99.1 BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent WESTPORT, CT, May 03, 2024 —BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or “the Company”), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced

Securities Purchase Agreement dated May 7, 2024 (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on May 7, 2024)

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 1, 2024, between BioSig Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions

Form of Common Stock Purchase Warrant dated May 7, 2024 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on May 7, 2024)

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 BioSig Technologies,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 BioSig Technologies,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 BioSig Technologies,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of in

BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately

Exhibit 99.1 BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately Mr. Amato will also serve on the Company’s Board of Directors WESTPORT, CT, April 30, 2024 —BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or “the Company”), a medical technology Company delivering unprecedented accuracy and precision to intra-cardiac signal visual

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 BioSig Technologie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 BioSig Technologies,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTON 13.0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 Or ☐ TRANSITION REPORT UNDER SECTON 13.08 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38659 BIOSIG TECHNOLOGIES, INC. (Exact

Certification of Chief Executive Officer and Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

EXHIBIT 31.01 CERTIFICATION I, Frederick D. Hrkac, certify that: 1. I have reviewed this annual report on Form 10-K of BioSig Technologies, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wit

Exhibit 4.1

EXHIBIT 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of April 15, 2024, BioSig Technologies, Inc., a Delaware corporation (“we,” “our” and the “Company”) has our common stock, par value $0.001 per share registered under Section 12 of the Securities Exchange Act of 1934, as amended. The foregoing description is intended as a summary and i

Compensation Recovery Policy adopted November 6, 2023

EXHIBIT 97 BIOSIG TECHNOLOGIES, INC. Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) of BioSig Technologies, Inc. (the “Company”) is hereby adopted as of November 6, 2023 in compliance with Rule 5608 of the Nasdaq Rules. Certain terms used herein shall have the meanings set forth in “Section 3. Definitions” below. Section 1. Recovery Requirement Subject to Section 4

Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

EXHIBIT 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Frederick D. Hrkac, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of BioSig Technologies, Inc. on Form 10-K for the f

SEC FILE NUMBER

OMB APPROVAL UNITED STATES OMB Number: 3235-0058 SECURITIES AND EXCHANGE COMMISSION Expires: April 30, 2025 Washington, D.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commission

Form of Note

Exhibit 4.1 THE SECURITY REPRESENTED HEREBY HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS SECURITY MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY, (B) IN COMPLIANCE WITH RULE 144 UNDER THE SECURITIES ACT, IF AVAILABLE, AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, (C) PURSUANT TO AN EFFECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 BioSig Technologies

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer of

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer

BSGM / BioSig Technologies, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

BioSig’s PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases

Exhibit 99.1 BioSig’s PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases ● Company sees clinical adoption and usage of its novel Near Field Tracking algorithm, proven to reduce ablation time by approximately 66%. Westport, CT, Feb. 06, 2024 (GLOBE NEWSWIRE) – BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company committ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 BioSig Technolog

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of incorporation) (Commiss

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Costs Associated with Exit or Disposal Activities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction of inc

Consulting Agreement, dated January 31, 2024

Exhibit 10.1 biosig technologies, Inc. CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is made and entered into (the “Effective Date”) by and between BioSig Technologies, Inc., a Delaware corporation with its principal place of business at 55 Greens Farms Rd 1st Floor Westport, CT 06880 (the “Company”), and , with a principal place of business/residence at (“Consultant”) (each he

Costs Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer

BioSig Announces Reverse Stock Split ● Common Stock Will Begin Trading on Split-Adjusted Basis on February 2, 2024

Exhibit 99.1 BioSig Announces Reverse Stock Split ● Common Stock Will Begin Trading on Split-Adjusted Basis on February 2, 2024 Westport, CT, January 31, 2024 (GLOBE NEWSWIRE) - BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it

Certificate of Amendment of Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc., dated January 31, 2024 (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on January 31, 2024)

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOSIG TECHNOLOGIES, INC. BioSig Technologies, Inc., (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The original Certificate of Incorporation of this Corporation was filed with the Secretary

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38659 26-4333375 (State or other jurisdiction (Commission (IRS Employer